Ana is a molecular biologist with a passion for discovery and communication. As a science writer, she looks for connecting the public, in particular patients and healthcare providers, with clear and quality information about the latest medical advances. Ana holds a Ph.D. in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in infectious diseases, epigenetics, and gene expression.
The immunotherapy candidate GEN-1 has shown encouraging results in patients newly diagnosed with advanced ovarian cancer, according to initial results of the OVATION 2 study. Adding GEN-1 to neoadjuvant ... Read more
Immune responses in women with advanced ovarian cancer being treated with DPX-Survivac in clinical trials continue to support the immunotherapy’s potential, alone or in combination, to be effective in this patient population. ... Read more
The U.S. Food and Drug Administration (FDA) has agreed to review AstraZeneca and Merck‘s request to extend the indication of oral Lynparza (olaparib) as a first-line maintenance therapy in combination ... Read more
Anixa Biosciences and Moffitt Cancer Center are seeking to develop a more potent version of their immunotherapy candidate for ovarian cancer, based on chimeric antigen receptor (CAR) T-cell technology, ... Read more
The U.K.’s National Institute for Health and Care Excellence, widely known as NICE, is recommending that Clovis Oncology‘s Rubraca (rucaparib) be available as a maintenance therapy for women with recurrent ... Read more
Rubraca (rucaparib), a therapy for relapsed or progressive ovarian, fallopian, or primary peritoneal cancer, was provisionally rejected for use on England’s National Health Service (NHS). In justifying its decision, ... Read more